A new analysis of older people taking tralokinumab with topical corticosteroids to treat moderate to severe atopic dermatitis saw a 75% or greater improvement of their eczema for 16 weeks, compared to those who took a placebo.
The results among a group of seniors 70 to 73 years old are important for older people who “typically face unique treatment challenges,” wrote study authors, led by Joseph F. Merola, MD, a researcher from Brigham and Women’s Hospital.
“Treatment for moderate-to-severe disease can be challenging, as they can experience more active and severe disease, increased comorbidity, polypharmacy, and a higher risk of infection,” the authors reported in JAMA Dermatology online ahead of print. “Other challenges include potential safety risks and low adherence to conventional therapies, like corticosteroids, phototherapy, and immunosuppressants.” n
From the November 2023 Issue of McKnight's Long-Term Care News
